1. Conn PM, Crowley WF.
Gonadotropin-releasing hormone and its analogs. Ann
Rev Med 1994;45:391-405.
2. The Leuprolide Study Group.
Leuprolide versus diethylstilbestrol for
metastatic prostate cancer. N Engl J Med
1984;311:1281-6.
3. Vogelzang NJ, et al.
Goserelin versus orchiectomy in the treatment of
advanced prostate cancer: final results of a
randomized trial. Urology 1995;46:220-6.
4. Kaisari AV, et al.
Comparison of LHRH analogue (Zoladex) with
orchiectomy in patients with metastatic prostate
cancer. Br J Urol 1991;67:502-8.
5. Parmar H, et al.
Orchiectomy versus long-acting DTrp6LHRH
in advanced prostatic cancer. Br J Urol
1987;59:248-54.
6. Sylvester RJ, et al. The
importance of prognostic factors in the
interpretation of two EORTC metastatic prostate
cancer trial. European organization for
Research and Treatment of Cancer (EORTC)
Genito-Urinary Tract Cancer Cooperative Group. Eur
Urol 1998;33:134-43.
7. Kienle E, Lubben G.
Efficacy and safety of leuprorelin acetate depot
for prostate cancer. The Gemen Leuprorelin Study
Group. Urol Int 1996;56 (Suppl
1):S23-30.
8. Robustelli della Cuna FS,
Robustelli della Cuna G. Ormoni antitumorali.
In: Bonadonna G, Robustelli della Cuna G.
Medicina Oncologica. 6° ed. 1999:633-58.
9. Taylor CW, et al.
Multicenter randomized clinical trial of
goserelin versus surgical ovariectomy in
premenopausal patients with receptor-positive
metastatic breast cancer: an intergroup study. J
Clin Oncol 1998;16:994-9.
10. Jonat W. Luteinizing
hormone-releasing hormone analogues - the
rationale for adjuvant use in premenopausal
women with early breast cancer. Br J Cancer
1998;78 (Suppl 4):S5-8.
11. Harvey HA, et al. Medical
castration produced by the GnRH leuprolide to
treat metastatic breast cancer. J Clin Oncol
1985;3:1068-72.
12. Marini L, et al. Direct
antiproliferative effect of triptorelin on human
breast cancer cells. Anticancer Res 1994;14:1881-5.
13. Garcia-Giralt E, et al.
Phase II trial of decapeptyl (D-TRP-6), a
potent luteinizing hormone-releasing hormone
analogue in untreated advanced breast cancer. Am
J Clin Oncol 1996;19:455-8.
14. Grumbach MM, Styne DM.
Puberty: ontogeny, neuroendocrinology,
physiology, and disorders. In: Wilson JD et al
eds. Williams textbook of endocrinology. 9th ed.
W. B. Saunders Company,1998:1509-625.
15. Boepple PA, et al. Use of
a potent, long-acting agonist of
gonadotropinreleasing hormone (GnRH) in the
treatment of precocious puberty. Endocr Rev
1986;7:24-33.
16. Boepple PA, et al. Impact
of sex steroids and their suppression of on
skeletal growth maturation. Am J Physiol
1988;255:559-66.
17. Meldrum DR, et al.
"Medina oophorectomy" using a
long-acting GnRH agonist - a possible new
approach to the treatment of endometriosis. J
Clin Endocrinol Metab 1982;54:1081-3.
18. Cedar MI, et al.
Treatment of endometriosis with a long-acting
gonadotropin-releasing hormone agonist plus
medroxyprogesterone acetate. Obstet Gynecol
1990;75:641-5.
19. Maheux R. Treatment of
uterine leiomyomata: past, present and future. Horm
Res 1989;32:125-33.